What this pack is
ATIVAN is the brand name in this record; lorazepam tablets is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
ATIVANGeneric namelorazepam tablets
How this medicine works
The current label identifies ATIVAN as a benzodiazepine CNS depressant and states in its interaction section that benzodiazepines act at GABA sites. This helps explain additive sedation and breathing risk with other CNS depressants, but cannot select an individual's dose, timing or substitute.
Read source: United States ↗Current regulatory record · reviewed 2026-09-04More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- ATIVAN
- Source-scoped market brand names
- ATIVAN · United StatesCurrent regulator record ↗NDA 017794; the current label lists three 100-tablet bottles at 0.5, 1 and 2 mg. A regulatory label does not prove live supply, purchase availability or individual suitability.
The evidence status and note below apply only to the stated market and source. They do not prove that packs in different markets can be substituted.
- Generic name
- lorazepam tablets
- Dosage-form class
- Dosage form and presentation as documented in the linked primary label
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
3 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed brand label (label revised Jul 2025; SPL v24)
Lorazepam 0.5 mg per tablet; 100-tablet bottle
- Product code
- NDC 0187-0063-01
- Form and route
- ATIVAN lorazepam immediate-release oral tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-04; actual marketing, stock and availability are not established.
- lorazepam
- 0.5 mglabelled amount per tablet; not an individual's tablet count, frequency, course, taper or stop instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- white · five-sided shield shape · imprint A / BPI / 63Unscored in this labelled presentation
United States label · Current U.S. DailyMed brand label (label revised Jul 2025; SPL v24)
Lorazepam 1 mg per tablet; 100-tablet bottle
- Product code
- NDC 0187-0064-01
- Form and route
- ATIVAN lorazepam immediate-release oral tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-04; actual marketing, stock and availability are not established.
- lorazepam
- 1 mglabelled amount per tablet; not an individual's tablet count, frequency, course, taper or stop instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- white · five-sided shield shape · imprint A / BPI / 64Scored product-identity clue; not permission to split it yourself
United States label · Current U.S. DailyMed brand label (label revised Jul 2025; SPL v24)
Lorazepam 2 mg per tablet; 100-tablet bottle
- Product code
- NDC 0187-0065-01
- Form and route
- ATIVAN lorazepam immediate-release oral tablet · oral
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-04; actual marketing, stock and availability are not established.
- lorazepam
- 2 mglabelled amount per tablet; not an individual's tablet count, frequency, course, taper or stop instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- white · five-sided shield shape · imprint A / 2 / BPI / 65Scored product-identity clue; not permission to split it yourself
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
ATIVAN enlarged label: mg per tablet, additive sedation, older-adult falls and abrupt withdrawal
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The 0.5, 1 and 2 mg figures are lorazepam per tablet; 100 Tablets is the bottle count. The 1 mg and 2 mg labels describe scores, but a score is an identity clue, not permission to self-split, taper or stop. The boxed warning covers opioid co-use, abuse/misuse/addiction, physical dependence and withdrawal reactions.
- Co-use with an opioid can cause profound sedation, respiratory depression, coma and death. Shallow or slow breathing, inability to awaken or marked altered awareness requires local emergency help; do not first seek a web spacing or self-reduction plan.
- Alcohol, another benzodiazepine, a sleep medicine, sedating antihistamine, antipsychotic, some antidepressants, anticonvulsants and anaesthetics can add CNS depression. Different brands do not permit rotation or combination.
- Continued use can cause physical dependence; abrupt discontinuation or rapid reduction can trigger life-threatening withdrawal, including seizures. Do not copy a web or another person's taper; the treating professional must individualise and follow it.
- Sedation and unsteadiness increase with age and some older people may be more sensitive. With many medicines, review sleepiness, gait, falls, memory, breathing, liver/kidney status and all OTC products together. The site does not derive a tablet count from age.
- The label states that valproate and probenecid can alter lorazepam exposure and that clozapine co-use can cause marked sedation, hypotension, ataxia, delirium and respiratory arrest. A clinician or pharmacist must review these interactions; self-spacing is not a solution.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-04
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 1
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. ATIVAN lorazepam brand label, Medication Guide and three 100-tablet bottle panels (label revised Jul 2025) ↗Current regulatory record · reviewed 2026-09-04
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about ATIVAN (lorazepam tablets). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
ATIVAN is the brand in this record and lorazepam tablets is the active-ingredient name. Check both with the dosage form (Dosage form and presentation as documented in the linked primary label) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. ATIVAN lorazepam brand label, Medication Guide and three 100-tablet bottle panels (label revised Jul 2025) ↗Current regulatory record · reviewed 2026-09-04
- DailyMed (NLM): FDA-approved ATIVAN lorazepam Medication Guide ↗Current regulatory record · reviewed 2026-09-04
HOW IT WORKS · NOT A TREATMENT PLAN
Mechanism reading: benzodiazepine action at GABA sites does not prove safe co-use
- ATIVAN, VALIUM, XANAX, KLONOPIN and LOREEV XR are not one product. Shared GABA-related or anxiety/sedation use creates no one-for-one milligram conversion or rotation table.
- Opioids act mainly at mu-receptor systems while benzodiazepines act at GABA sites; different mechanisms can still jointly depress breathing and alertness, so a time gap cannot be inferred to make co-use safe.
- This mechanism section cannot decide genetic testing, a switch to another anxiolytic or tablet splitting. Those decisions require the diagnosis, exact pack, prescription, full medicine list and professional assessment.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. ATIVAN lorazepam brand label, Medication Guide and three 100-tablet bottle panels (label revised Jul 2025) ↗Current regulatory record · reviewed 2026-09-04
- DailyMed (NLM): FDA-approved ATIVAN lorazepam Medication Guide ↗Current regulatory record · reviewed 2026-09-04
- FDA: multidisciplinary LORazepam ER (Loreev XR) review identifying ATIVAN NDA 017794 as the listed drug and recording initial approval on 30 Sep 1977 ↗reviewed 2026-09-04
- FDA: ATIVAN NDA 017794/S-049 supplemental safety-labelling approval letter covering overdose, neonatal withdrawal and pregnancy/lactation risks ↗reviewed 2026-09-04
SOURCE-TRACEABLE ARCHIVE
ATIVANlorazepam tablets
This page includes an exact current U.S. public-label package panel for ATIVAN, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval of ATIVAN lorazepam tablets
A later FDA multidisciplinary review identifies ATIVAN tablets as the listed drug and records NDA 017794 with this initial approval date.
FDA: multidisciplinary LORazepam ER (Loreev XR) review identifying ATIVAN NDA 017794 as the listed drug and recording initial approval on 30 Sep 1977 ↗FDA approved the S-049 safety-label supplement
The supplement revised labeling for overdose, neonatal withdrawal syndrome and pregnancy/lactation-related risks.
FDA: ATIVAN NDA 017794/S-049 supplemental safety-labelling approval letter covering overdose, neonatal withdrawal and pregnancy/lactation risks ↗Current brand-label revision date
The current DailyMed label and Medication Guide list three exact 100-tablet bottles, boxed warnings and older-adult reading priorities.
DailyMed (NLM): current U.S. ATIVAN lorazepam brand label, Medication Guide and three 100-tablet bottle panels (label revised Jul 2025) ↗
MARKET SCOPE
Market-record boundary
United States
Current public brand labelNDA 017794; 0.5, 1 and 2 mg in three 100-tablet bottles; U.S. C-IV. Label status is not live supply or individual suitability.
Mainland China, EU, Japan and other markets
Local brand, approval, reference, controlled-drug class, pack and supply are not yet established market by marketNo other-market status is inferred from the U.S. ATIVAN name, NDA, NDC, C-IV class or package appearance.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Do 0.5 mg, 1 mg and 2 mg tell me how many tablets to take?
No. They are labelled amounts per tablet; 100 Tablets is the bottle count. Individual tablet count, frequency, course and taper/stop plan must come from the actual prescription and treating professional.
The 1 mg and 2 mg tablets are scored. Can I split one myself?
A score does not itself grant permission. It first helps identify the exact product; the prescriber must confirm whether it may be split and how any dose change or stop is handled.
Is it safe if separated from a pain medicine, sleep medicine or alcohol by a few hours?
The site cannot make that conclusion. Opioid and other CNS-depressant effects can persist and add. Give the full list, alcohol use and timing to a clinician or pharmacist. Shallow breathing or inability to awaken requires immediate emergency help.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.